Adenovirus-based vaccines: Comparison of vectors from three species of adenoviridae

Journal of Virology

Volumn 84, Issue 20, 2010, Pages 10522-10532

  Chen, H ^a,e   Xiang, Z Q ^a   Li, Y ^a   Kurupati, R K ^a   Jia, B ^a,f   Bian, A ^a   Zhou, D M ^a   Hutnick, N ^b   Yuan, S ^b   Gray, C ^b   Serwanga, J ^c   Auma, B ^d   Kaleebu, P ^d   Zhou, X ^a   Betts, M R ^b   Ertl, H C J ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

^e TONGJI UNIVERSITY   (China)

^f CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; NEUTRALIZING ANTIBODY; VIRUS VACCINE;

ADENOVIRUS; AFRICA; ANIMAL CELL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CAMEROON; CD8+ T LYMPHOCYTE; COTE D'IVOIRE; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS 26; HUMAN ADENOVIRUS 5; HUMAN CELL; IMMUNE RESPONSE; MOUSE; NIGERIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECEPTOR BINDING; SEROPREVALENCE; SEROTYPE; SIMIAN VIRUS; SIMIAN VIRUS 23; SIMIAN VIRUS 24; THAILAND; TRANSGENE; UGANDA; UNITED STATES; VIRUS CAPSID;

ADENOVIRIDAE; ADENOVIRUSES, HUMAN; ADENOVIRUSES, SIMIAN; ADULT; AFRICA SOUTH OF THE SAHARA; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICE, INBRED BALB C; RABIES VIRUS; RECEPTORS, VIRUS; RECOMBINANT PROTEINS; SEROEPIDEMIOLOGIC STUDIES; SEROTYPING; SPECIES SPECIFICITY; VIRAL VACCINES;

ADENOVIRIDAE; MUS; PAN; SIMIAE;

EID: 77957204031     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00450-10     Document Type: Article

References (32)

1. Abbink, P., A. A. Lemckert, B. A. Ewald, D. M. Lynch, M. Denholtz, S. Smits, L. Holterman, I. Damen, R. Vogels, A. R. Thorner, K. L. O'Brien, A. Carville, K. G. Mansfield, J. Goudsmit, M. J. Havenga, and D. H. Barouch. 2007. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81:4654-4663.
2. Amara, R. R., J. M. Smith, S. I. Staprans, D. C. Montefiori, F. Villinger, J. D. Altman, S. P. O'Neil, N. L. Kozyr, Y. Xu, L. S. Wyatt, P. L. Earl, J. G. Herndon, J. M. McNicholl, H. M. McClure, B. Moss, and H. L. Robinson. 2002. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 76:6138-6146.
3. Bansal, G. P., A. Malaspina, and J. Flores. Future paths for HIV vaccine research: exploiting results from recent clinical trials and current scientific advances. Curr. Opin. Mol. Ther. 12:39-46.
4. Buchbinder, S. P., D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J. R. Lama, M. Marmor, C. Del Rio, M. J. McElrath, D. R. Casimiro, K. M. Gottesdiener, J. A. Chodakewitz, L. Corey, and M. N. Robertson. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893.
5. Fitzgerald, J. C., G. P. Gao, A. Reyes-Sandoval, G. N. Pavlakis, Z. Q. Xiang, A. P. Wlazlo, W. Giles-Davis, J. M. Wilson, and H. C. Ertl. 2003. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 170:1416-1422.
6. Gaggar, A., D. M. Shayakhmetov, and A. Lieber. 2003. CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9:1408-1412.
7. Harro, C., X. Sun, J. E. Stek, R. Y. Leavitt, D. V. Mehrotra, F. Wang, A. J. Bett, D. R. Casimiro, J. W. Shiver, M. J. DiNubile, and E. Quirk. 2009. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clin. Vaccine Immunol. 16:1285-1292.
8. + T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J. Immunol. 175:6032-6041.
9. Hill, A. V., A. Reyes-Sandoval, G. O'Hara, K. Ewer, A. Lawrie, A. Goodman, A. Nicosia, A. Folgori, S. Colloca, R. Cortese, S. C. Gilbert, and S. J. Draper. Prime-boost vectored malaria vaccines: progress and prospects. Hum. Vaccin. 6:78-83.
10. Reference deleted.
11. + T cells. Nat. Med. 15:876-878.
12. Hutnick, N. A., D. Carnathana, K. Demers, G. Makedonas, H. C. J. Ertl, and M. R. Betts. 2010. Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive. Vaccine 23:1932-1941.
13. Liu, J., B. A. Ewald, D. M. Lynch, M. Denholtz, P. Abbink, A. A. Lemckert, A. Carville, K. G. Mansfield, M. J. Havenga, J. Goudsmit, and D. H. Barouch. 2008. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J. Virol. 82:4844-4852.
14. Liu, J., K. L. O'Brien, D. M. Lynch, N. L. Simmons, A. La Porte, A. M. Riggs, P. Abbink, R. T. Coffey, L. E. Grandpre, M. S. Seaman, G. Landucci, D. N. Forthal, D. C. Montefiori, A. Carville, K. G. Mansfield, M. J. Havenga, M. G. Pau, J. Goudsmit, and D. H. Barouch. 2009. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457:87-91.
15. Mast, T. C., L. Kierstead, S. B. Gupta, A. A. Nikas, E. G. Kallas, V. Novitsky, B. Mbewe, P. Pitisuttithum, M. Schechter, E. Vardas, N. D. Wolfe, M. Aste-Amezaga, D. R. Casimiro, P. Coplan, W. L. Straus, and J. W. Shiver. 2010. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28:950-957.
16. McCoy, K., N. Tatsis, B. Korioth-Schmitz, M. O. Lasaro, S. E. Hensley, S. W. Lin, Y. Li, W. Giles-Davis, A. Cun, D. Zhou, Z. Xiang, N. L. Letvin, and H. C. Ertl. 2007. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J. Virol. 81:6594-6604.
17. McElrath, M. J., S. C. De Rosa, Z. Moodie, S. Dubey, L. Kierstead, H. Janes, O. D. Defawe, D. K. Carter, J. Hural, R. Akondy, S. P. Buchbinder, M. N. Robertson, D. V. Mehrotra, S. G. Self, L. Corey, J. W. Shiver, and D. R. Casimiro. 2008. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372:1894-1905.
18. O'Brien, K. L., J. Liu, S. L. King, Y. H. Sun, J. E. Schmitz, M. A. Lifton, N. A. Hutnick, M. R. Betts, S. A. Dubey, J. Goudsmit, J. W. Shiver, M. N. Robertson, D. R. Casimiro, and D. H. Barouch. 2009. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat. Med. 15:873-875.
19. Pichla-Gollon, S. L., S. W. Lin, S. E. Hensley, M. O. Lasaro, L. Herkenhoff-Haut, M. Drinker, N. Tatsis, G. P. Gao, J. M. Wilson, H. C. Ertl, and J. M. Bergelson. 2009. Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo. J. Virol. 83:5567-5573.
20. Radosevic, K., C. W. Wieland, A. Rodriguez, G. J. Weverling, R. Mintardjo, G. Gillissen, R. Vogels, Y. A. Skeiky, D. M. Hone, J. C. Sadoff, T. van der Poll, M. Havenga, and J. Goudsmit. 2007. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect. Immun. 75:4105-4115.
21. Reyes-Sandoval, A., J. C. Fitzgerald, R. Grant, S. Roy, Z. Q. Xiang, Y. Li, G. P. Gao, J. M. Wilson, and H. C. Ertl. 2004. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J. Virol. 78:7392-7399.
22. Roelvink, P. W., A. Lizonova, J. G. Lee, Y. Li, J. M. Bergelson, R. W. Finberg, D. E. Brough, I. Kovesdi, and T. J. Wickham. 1998. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol. 72:7909-7915.
23. Roy, S., G. Gao, Y. Lu, X. Zhou, M. Lock, R. Calcedo, and J. M. Wilson. 2004. Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. Hum. Gene Ther. 15:519-530.
24. Singh, N., A. Pandey, L. Jayashankar, and S. K. Mittal. 2008. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol. Ther. 16:965-971.
25. Tatsis, N., A. Blejer, M. O. Lasaro, S. E. Hensley, A. Cun, L. Tesema, Y. Li, G. P. Gao, Z. Q. Xiang, D. Zhou, J. M. Wilson, and H. C. Ertl. 2007. A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Mol. Ther. 15:608-617.
26. + T cells: implications for their use as vaccines. Blood 110:1916-1923.
27. Xiang, Z., G. Gao, A. Reyes-Sandoval, C. J. Cohen, Y. Li, J. M. Bergelson, J. M. Wilson, and H. C. Ertl. 2002. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 76:2667-2675.
28. Xiang, Z., Y. Li, A. Cun, W. Yang, S. Ellenberg, W. M. Switzer, M. L. Kalish, and H. C. Ertl. 2006. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg. Infect. Dis. 12:1596-1599.
29. Xiang, Z. Q., S. Spitalnik, M. Tran, W. H. Wunner, J. Cheng, and H. C. Ertl. 1994. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology 199:132-140.
30. Xiang, Z. Q., Y. Yang, J. M. Wilson, and H. C. Ertl. 1996. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219:220-227.
31. Yuan, Z. G., X. M. Li, Y. S. Mahmmod, X. H. Wang, H. J. Xu, and X. X. Zhang. 2009. A single immunization with a recombinant canine adenovirus type 2 expressing the Seoul virus Gn glycoprotein confers protective immunity against Seoul virus in mice. Vaccine 27:5247-5251.
32. Reference deleted.